This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. For a great company, an IPO is a financing event. Not an exit. Not the end. This is important to

Imagine you were an investor version of Rip Van Winkle. You went to sleep in October 2012 and woke up today. You’d take a quick look at biotech and think we were in a raging bull market. A few thoughts

Venture capital in biotech has had a great run over the past few years: funding going to private biotech companies is at historic highs, new venture funds are getting raised, and exits have been happening via robust IPO and M&A

This blog was written by Vanessa King, CEO of Luc Therapeutics (f.k.a. Mnemosyne Pharmaceuticals), as part of the “From the Trenches” feature of LifeSciVC. High winds and cold rain certainly make a first impression – and that was even before I’d

Yesterday we were excited to see four Atlas portfolio companies selected to receive “Fierce15” awards from FierceBiotech as part of the 2015 “class”. It’s a wonderful honor for them, and for Atlas, and thought it a great moment to reflect

The relative absence of women from significant leadership roles in the biotech industry has rightfully become a front-and-center topic, in part prompted by a wave of coverage on the subject (here, here, here, here). Liftstream’s recent report, titled “Diversifying the

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. A few weeks ago, a member of our board sent an email to a group of biotech CSOs suggesting that

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. After many months (or years) of grinding, your science seems to be working, the market is responding to your story,

With the NASDAQ sector indices still up 17% for the year, and IPOs continuing at a robust pace, the biotech investing climate continues to be an exciting one. Amidst these rising stock prices, or at least perceptions, I frequently get

Biotech has been on a tear over the past few years supported by a combination of scientific advances, great IPO and M&A exit environments, and robust capital markets for fundraising. Watching the public indices gives a good indicator of broader

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. I had an interesting discussion with a veteran of a rapidly growing biotech. He’d been at his company at the

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. We all have stuff lying around our homes or offices that we have no further use for but that might be